Quantcast

Latest Caphosol Stories

2009-07-23 08:00:00

DALLAS, July 23 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP), announced today that its European partner, SpePharm, is collecting data from a post approval study of MuGard in head and neck cancer patients undergoing radiation treatment in the UK showing prevention of oral mucositis. In a multi-center study expected to enroll a total of 280 patients, patients are provided with seven weeks of MuGard therapy, and begin using MuGard one week prior to...

2009-06-10 08:00:00

Commercial Launch of MuGard in Europe Ongoing DALLAS, June 10 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP), announced today that the Company has received issue notifications from the United States Patent and Trademark Office that two US patents relating to MuGard(TM), the Company's approved oral rinse product for the management of mucositis will issue in June as US Patent numbers 7,544,348 and 7,547,433. MuGard is a novel, ready-to-use mucoadhesive oral...

2009-05-27 07:30:00

NEW FDA-APPROVED TREATMENT FOR ORAL MUCOSITIS DALLAS, May 27 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP), (http://www.accesspharma.com) announced today that MuGard(TM), its proprietary oral mucositis product has been launched in Germany, Italy, UK, Greece and the Nordic countries by its European commercial partner, SpePharm, a pan-European specialty pharmaceutical company dedicated to the provision of high medical value medicines in supportive and...

2009-04-22 08:00:00

DALLAS, April 22 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP), announced today that MuGard(TM), its proprietary polymer-based oral mucositis product has been launched in Germany, Italy, UK, Greece and the Nordic countries by its European commercial partner, SpePharm, a pan-European specialty pharmaceutical company dedicated to the provision of high medical value medicines in supportive and critical care. Under a license from Access Pharmaceuticals Inc,...

2009-03-31 04:00:00

DOYLESTOWN, Pennsylvania and OXFORD, England, March 31 /PRNewswire/ -- EUSA Pharma Inc ('EUSA'), a transatlantic specialty pharmaceutical company focused on oncology, pain control and critical care, announced today the successful completion of its European launch of CAPHOSOL(R) for the prevention and treatment of oral mucositis associated with cancer therapy, as an adjunct to standard oral care. CAPHOSOL is also indicated for hyposalivation and xerostomia (dryness of the mouth or throat)...

2009-02-19 07:00:00

Transaction Value in Excess of $10 Million; Access Gains Second Source Manufacturing and Significant Clinical Trial Support DALLAS, and SEOUL, South Korea, Feb. 19 /PRNewswire-FirstCall/ -- Access Pharmaceuticals, Inc. (OTC Bulletin Board: ACCP) and JCOM Ltd, an affiliate of DONG-A Pharmaceuticals, the premier pharmaceutical company in the Republic of Korea, today announced the signing of a definitive licensing agreement under which JCOM and DONG-A will manufacture, develop and...

2008-10-17 18:00:23

A U.S. cancer specialist says there is little public awareness about a common cancer therapy side effect -- oral mucositis. Dr. James D'Olimpio of New York University School of Medicine and director of Supportive Oncology/Pain and Symptom Management at the Monter Cancer Center of North Shore University Hospital in Manhasset, N.Y., says an overwhelming majority -- 90 percent -- of more than 400 oral mucositis patients said this chemotherapy and radiation effect adversely affected their...

2008-10-16 06:00:10

PRINCETON, N.J., Oct. 16 /PRNewswire/ -- As millions of Americans participate in educational initiatives as part of National Breast Cancer Awareness Month, they should keep in mind an important yet under-recognized consequence of breast cancer therapy: oral mucositis, one of the most common and debilitating side effects of cancer treatment. Oral mucositis (OM) is a painful inflammation/ulceration of the mucous membranes in the mouth. It results from erosion of epithelial cells in the oral...

2008-09-03 00:00:24

Anadis Ltd. (ASX:ANX; OTC:ANDIY) an Australian biopharmaceutical company specializing in oral immunotherapy using naturally derived antibodies and other proteins is announcing the clinical protocol for its Cancer-related Mucositis Program was cleared by the Tel Aviv Souraski Medical Center's Institutional Review Board (IRB) and by the Israeli Ministry of Health (MOH). This enables the initiation of the clinical trial addressing this significant target at the medical center within a month....

2008-08-18 09:01:02

DALLAS, Aug. 18 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC. (BULLETIN BOARD: ACCP) and Milestone Biosciences, LLC ("Milestone") today announced the signing of a definitive license agreement under which Milestone will market Access' proprietary product MuGard(TM) in the United States and Canada. Milestone is a company recently started by former executives and sales representatives of companies with an established commercial presence in oncology, including MGI Pharma, Amgen and...